Gallinat Anja, Leerhoff Sabine, Paul Andreas, Molmenti Ernesto P, Schulze Maren, Witzke Oliver, Sotiropoulos Georgios C
Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, Hufelandstraße 55, 45122, Essen, Germany.
Department of Surgery, North Shore University Hospital, Manhasset, NY, USA.
Langenbecks Arch Surg. 2016 Dec;401(8):1211-1217. doi: 10.1007/s00423-016-1445-9. Epub 2016 Jun 8.
Elevated donor serum creatinine has been associated with inferior graft survival in kidney transplantation (KT). The aim of this study was to evaluate the impact of elevated donor serum creatinine on short and long-term outcomes and to determine possible ways to optimize the use of these organs.
All kidney transplants from 01-2000 to 12-2012 with donor creatinine ≥ 2 mg/dl were considered. Risk factors for delayed graft function (DGF) were explored with uni- and multivariate regression analyses. Donor and recipient data were analyzed with uni- and multivariate cox proportional hazard analyses. Graft and patient survival were calculated using the Kaplan-Meier method.
Seventy-eight patients were considered. Median recipient age and waiting time on dialysis were 53 years and 5.1 years, respectively. After a median follow-up of 6.2 years, 63 patients are alive. 1, 3, and 5-year graft and patient survival rates were 92, 89, and 89 % and 96, 93, and 89 %, respectively. Serum creatinine level at procurement and recipient's dialysis time prior to KT were predictors of DGF in multivariate analysis (p = 0.0164 and p = 0.0101, respectively). Charlson comorbidity score retained statistical significance by multivariate regression analysis for graft survival (p = 0.0321). Recipient age (p = 0.0035) was predictive of patient survival by multivariate analysis.
Satisfactory long-term kidney transplant outcomes in the setting of elevated donor serum creatinine ≥2 mg/dl can be achieved when donor creatinine is <3.5 mg/dl, and the recipient has low comorbidities, is under 56 years of age, and remains in dialysis prior to KT for <6.8 years.
在肾移植(KT)中,供体血清肌酐升高与移植肾存活率较低相关。本研究的目的是评估供体血清肌酐升高对短期和长期结局的影响,并确定优化这些器官使用的可能方法。
纳入2000年1月至2012年12月期间供体肌酐≥2mg/dl的所有肾移植病例。通过单因素和多因素回归分析探索移植肾功能延迟(DGF)的危险因素。使用单因素和多因素考克斯比例风险分析对供体和受体数据进行分析。采用Kaplan-Meier法计算移植肾和患者存活率。
共纳入78例患者。受体年龄中位数和透析等待时间分别为53岁和5.1年。中位随访6.2年后,63例患者存活。1年、3年和5年的移植肾和患者存活率分别为92%、89%、89%和96%、93%、89%。在多因素分析中,获取时的血清肌酐水平和KT前受体的透析时间是DGF的预测因素(分别为p = 0.0164和p = 0.0101)。通过多因素回归分析,Charlson合并症评分对移植肾存活具有统计学意义(p = 0.0321)。多因素分析显示,受体年龄(p = 0.0035)是患者存活的预测因素。
当供体肌酐<3.5mg/dl,受体合并症少、年龄<56岁且KT前透析时间<6.8年时,在供体血清肌酐≥2mg/dl的情况下可实现令人满意的长期肾移植结局。